Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

NCT02673333 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Adrenocortical Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]